Ozempic, a diabetes drug turned weight-loss sensation, generated billions in annual sales, with U.S. pharmacies filling ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of ...

Van Ness, 37, turned to a weight loss medication to assist him in his efforts, and clearly all his hard work and dedication ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Discover how Hims & Hers Health closed 2024 with strong growth, expanding weight-loss solutions, and innovation-focused investments in ...

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...

Besides Mankind, Natco Pharma, Dr Reddy’s, Sun Pharma and others are already gearing up for launches of weight-loss drugs ...

The startling findings raise the possibility that the medicines, originally developed to treat diabetes, could one day be ...

THE family of a man who died after taking Mounjaro want a probe into the weight-loss drug’s “potential to kill”. It comes after The Sun revealed 82 deaths have been linked to anti-fat and diabetes ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...